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Abstract 
Aims: To determine the success rates of the surgical and non-surgical treatments in the management of bisphospho-
nate-related osteonecrosis of the jaws (BRONJ).
Material and Methods: A systematic review of the literature was made. A PubMed Medline database search was 
performed in order to include clinical studies published in English, between 2004 and 2014 with the following key-
words: “BRONJ AND treatment” and “NOT osteoporosis”. The following data was gathered: authors, title, year of 
publication, aim of study, level of evidence, sample size, treatment performed, treatment outcomes and follow-up. 
Studies including more than 20 patients with at least 6 months of follow-up, and that specify the different treatment 
approaches and their outcomes were included. Systematic reviews were excluded. All studies were classified accor-
ding to the SORT criteria (Strength of Recommendation Taxonomy).
Results: The initial electronic search yielded 169 papers, and 13 studies were added after a manual search (total of 
182 studies). After analysing the title and abstract and removing duplicates, 31 full-texts were obtained. A total of 
12 papers were finally included. Two were classified as level 3 evidence and 9 as level 2. The quality of the selected 
studies and the risk of bias were also reported.
Conclusions: Surgical treatments like sequestrectomy, surgical debridement and bone osteotomies provide suc-
cessful treatment outcomes, with success rates ranging from 58 to 100%. Controlled randomized clinical trials with 
larger samples and longer follow-up are needed to support these findings.
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Introduction
In 2003, Marx reported 36 cases of necrotic bone ex-
posed in the jaws associated with the long-term use of 
bisphosphonates (1). Since then, a high number of ca-
ses of bisphosphonate-related osteonecrosis of the jaws 
(BRONJ) have been documented. Most BRONJ are 
associated with the intravenous bisphosphonates admi-
nistration (IVBP), although some cases have also been 
described after oral intake of these agents (2).
In 2009, the American Association of Oral and Maxillo-
facial Surgery (AAOMS) published a staging system in 
order to classify each case of BRONJ according to its 
signs and symptoms; and to propose different treatment 
approach (3).
Several therapeutic strategies have been recommended in 
the literature according to the severity of this complication, 
ranging from strictly conservative to aggressive surgical 
approaches (4). The treatment of BRONJ is still under de-
bate, and most reports show different outcomes (5).
In the latest stage-dependent recommendations of the 
AAOMS, Ruggiero et al. (3) proposed a conservative 
regime with antibiotics, antibacterial mouthrinses, and 
pain control in stage 0 and stage I. When the patient is 
classified in stage II, a superficial debridement with re-
moval of the bone sequestrum is recommended to relieve 
soft tissue irritation and finally, in stage III, surgical de-
bridement with partial or total bone resection of the jaws 
should be considered. However, these recommendations 
are not widely followed. In fact, many papers suggest 
different approaches with varying success rates, depen-
ding on the characteristics of the sample. For this reason, 
a systematic review of the available literature was made 
in order to assess which treatment has a higher success 
rate in patients diagnosed with BRONJ.
Material and Methods
A literature search was performed using the Medline-
PubMed database in April 2014 with the following key-
words: “BRONJ AND treatment” and “NOT osteoporo-
sis”. Papers published in the last 10 years were analyzed 
and studies that addressed only oral bisphosphonates 
patients were excluded. When samples were composed 
by both IV and oral bisphosphonates, a separate analysis 
was made, retrieving only the IVBP data. 
The following inclusion criteria were applied: papers in 
English, studies in humans, samples with more than 20 pa-
tients, trials that described the applied treatment and outco-
me. Systematic reviews and studies with a post-treatment 
follow-up of less than 6 months were excluded. 
Two independent researchers decided the inclusion and/
or exclusion criteria of the studies included in the pre-
sent systematic review.
The following variables of each article were recorded: 
number of cases, age, gender, primary diagnosis, IVBP 
drug, duration of the IVBP treatment, BRONJ location, 
staging (according to Ruggeiro et al. (3)), and applied 
therapy. Also, treatment outcomes and follow-up time 
were assessed. Papers that did not record all these varia-
bles were excluded.
The treatment was considered successful when the pa-
tient improved the stage of the disease or when there 
was absence of bone exposure with proper healing, and 
the patient remained asymptomatic without any clinical 
signs of infection.
This systematic review followed-up the PRISMA guide-
lines (Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses) (6) and all papers were classified 
according to their scientific evidence level using the 
SORT criteria (Table 1).
Results
The initial electronic search using the terms “BRONJ” 
AND “treatment” NOT “osteoporosis” yielded 169 pa-
pers (Fig. 1), and 13 studies were added after a manual 
search (total of 182 studies). After an initial evaluation, 
the authors decided to include the search term “NOT 
oral”, resulting in 57 relevant papers. After analysing the 
title and abstract and removing duplicates, 31 full-texts 
were obtained. A total of 12 papers complying with the 
inclusion/exclusion criteria were finally included. The 
level of evidence of the papers included in this systema-
tic review according to the SORT classification can be 
seen in table 1.
Finally, the quantitative synthesis of the 12 papers of this 
systematic review is presented in table 2. The success 
rate of the surgical management of BRONJ ranges from 
58% to 100%, while the pharmacological approach, ba-
sed on antibacterial agents (antibiotics and antiseptic 
mouthrinses), has worse results (range: 33% to 100%).
Discussion
The lack of standardized success criteria and treatment 
protocols is one of the main limitations of this review. 
Furthermore, the use of several types of surgical thera-
pies (sequestrectomy and bone resection among others) 
and its association with several antibiotics and antisep-
tics also makes difficult to draw conclusions on which is 
the best treatment for BRONJ.
One of the advantages of using a more conservative sur-
gical approach like sequestrectomy is that a better healing 
should be expected since the periosteum and unaffected 
bone are conserved (7). On the other hand, a correct bone 
resection with a tension-free closure of soft tissues allows 
achievable and predictable results. In a recent review, the 
authors observed a 85-100% of success rate in wound 
healing without complications after surgery (8).
Most authors (6,9-14) achieved a good result with a sur-
gical treatment based either in local debridement and 
sequestrectomy or in bone resection. Aggressive thera-
pies with segmental resection of the affected bone with 
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Authors and year Study type 
Randomized 
YES/NO
Blind
YES/NO
Sample-size 
calculation 
YES/NO
Control
group
YES/NO
Level of 
evidence 
Junquera et al. 2009 (9)  Case series 
Retrospective 
NO NO NO NO 3 
Hoefert and Eufinger. 
2011 (4)  
Cohort study 
Retrospective 
NO NO NO NO 2 
Bedogni et al. 2011 (10)  Cohort study 
Prospective
NO NO NO NO 3 
Mücke et al. 2011 (11)  Cohort study 
Retrospective 
NO NO NO NO 2 
Nicolatou-Galitis et al.
2011 (25)  
Experimental study NO NO NO NO 2 
Martins et al. 2012 (12)  Cohort study 
Retrospective 
NO NO NO NO 2 
Wutzl et al. 2012 (5)  Cohort study 
Retrospective 
NO NO NO NO 2 
Fortuna et al. 2012 (26)  Experimental study NO NO NO NO 2 
Mozzati et al. 2012 (13)  Cohort study 
Retrospective 
NO NO NO NO 2 
Ferlito et al. 2012 (14)  Cohort study NO NO NO NO 2 
Graziani et al. 2012 (18)  Cohort study 
Retrospective 
NO NO NO NO 2 
Lerman et al. 2013 (27)  Cohort study 
Retrospective 
NO NO NO NO 2 
Table 1. Scientific evidence level of the reports included in this systematic review. 
Fig. 1. Flow-chart diagram search strategy.
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
Authors
andyear
N.
cases
Age
(y)

Gender
M/F
Cancer
diagnosis
IVBPP
used
Duration
trt.IVBPP
(mo)
BRONJlocation
onthejaws
MB/MX/BJ(%)
BRONJstage
S0/S1/S2/S3(%) BRONJtreatment
Treatment
outcomes
FollowͲ
up
(mo)
Junquera
etal.2009
(9)
20 51Ͳ84
5

15

13BC;
2PC;5MM 19Z;1P
11,2
(9Ͳ19) 80 20 Ͳ Ͳ 35 40 25
55%Sequestrectomy 100%Remission
6Ͳ30
45%ATBtherapy+
mouthrinses 33,3%Remission
Hoefert
and
Eufinger.
2011(4)
46 43Ͳ85 11 35
11MM;
27BC;2LC;
4PC;2KC
18Z;
7P+Z;5P;
5I;3I+Z;
2Cl+Z;
2P+Z+I;
1P+I;1A+
Z;1P+Z+E
;1Cl+Z+P
(5Ͳ129) 70 11 19 Ͳ 22 78 Ͳ
65%ATBtherapyfor4Ͳ
7weeks
+sequestrectomy
87%Remission
17
35%ATBtherapyfor1
week+sequestrectomy 47%Remission
Bedogniet
al.2011
(10)
30 46Ͳ80 6 24
13BC;
10MM;
3PC;2LC;
1TC;1AML
26Z;4P Ͳ 50 43 7 33 Ͳ 27 40
80%Bonesegmental
resection+hyperbaric
oxygentherapy 90,6%Remission 24
20%Bonesegmental
resectionofthejaws
Mückeet
al.2011
(11)
91 69±11 Ͳ Ͳ
39MM;
31BC;
16PC;
2KC;2Ly;
1LC
91Z 44,4(6Ͳ84) 72 21 7 Ͳ 16 43 41
90,7%Sequestrectomy
/totalormarginalbone
resection
71,3%Remission
6Ͳ12
9,3%ATBtherapy+
mouthrinses 60%Remission
NicolatouͲ
Galitiset
al.
2011(25)
31 40Ͳ86 3 28
37MM;
16BC;
5PC;1LC
41Z;
10P+Z;
6Z+I;1I;
1P+Z+I
37,1
(1Ͳ120) 62 30 8 19 33 38 10
100%ATBtherapy+
mouthrinses
91,5%Total/
partialremission
ofsymptoms
2Ͳ48
Martinset
al.2012
(12)
22 42Ͳ90 6 16
13BC;
6PC;
2MM;1LC
18Z;4P 24,68(8Ͳ48) 77 14 9 Ͳ 41 45 14
64%Boneresection+
PRP+InGaAlPdiode
lasertherapy
86%Remission
623%Sequestrectomy/bo
neresection 60%Remission
13%ATBtherapy+
mouthrinses 33%Remission
Wutzetal.
2012(5) 35 32Ͳ92 14 21
20MM;
9BC;3PC;
2LC;1AnC
25Z;5P;
5P+Z Ͳ 63 27 10 Ͳ 24 59 17
100%Surgical
treatment
(sequestrectomy/
extendedbone
resection/
osteosynthesis)
58%Remission 6
Fortunaet
al.2012
(26)
26 59Ͳ76 13 13 13BC;13MM 26Z >6 50 35 15 Ͳ Ͳ 38 62
100%ATBtherapy+
mouthrinses 84,6%Remission 6Ͳ12
Mozzatiet
al.2012
(13)
32 44Ͳ83 10 22
14MM;
6PC;5BC;
4LC;3OC
26Z;6P 37 75 25 Ͳ Ͳ Ͳ 100 Ͳ
100%Boneresection+
Plasmarichingrowth
factors
100%Remission 45Ͳ60
Ferlitoet
al.2012
(14)
77 66±11 25 52 Ͳ 72Z;4N;1I (6Ͳ24) Ͳ Ͳ Ͳ Ͳ 1 99 Ͳ
100%ATBtherapy+
mouthrinses+
sequestrectomy
100%Remission 6
Grazianiet
al.2012
(17)
304 34Ͳ92 103 201
126MM;
99BC;
34PC;
23CoC;
22TC
241Z;
41P;22Cl
23
(1Ͳ71) 65 29 6 Ͳ 28 60 12
65,4%Local
debridement 49%Remission
>6
34,6%Resectivesurgery 68%Remission
Lermanet
al.2013
(27)
108 39Ͳ91 54 54
71MM;
26BC;4LC;
4PC;1CC;
1L;1KC
66Z;19P;
18P+Z;
3A+P+R+
Z;
1A+P+Z;
1R+Z
24
(0Ͳ126) 71 18 12 14 41 43 5
16%Observation,
mouthrinses
78%Remission 6Ͳ64
55%ATBtherapy+
mouthrinses
14%Sequestrectomy+
ATBtherapy
14%Boneresection+
ATBtherapy
Table 2. Studies selected according to the inclusion criteria. Features of the cases of each study, BRONJ treatment and outcomes. 
Abbreviations: y, years; mo, months; M, male; F, female; trt., treatment; MB, mandible; MX, maxilla; BJ, both jaws; S, stage; Ca, cancer; BC, 
breast cancer; PC, prostate cancer; LC, lung cancer; MM, multiple myeloma ; AnC, anal cancer; TC, thyroid cancer; CC, cervical cancer; KC, 
kidney cancer; OC, ovarian cancer; L, leiomyosarcoma; Ly, lymphoma; AML, acute myeloid leukemia; IVBP, intravenous bisphosphonate; Z, 
zoledronate; P, pamidronate; I, ibandronate; Cl, clodronate; A, alendronate; E, etidronate; R, risedronate; N, neridronate. 
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inclusion of the periosteal layer combined with hyperba-
ric oxygen therapy (HBO) also seem effective (10). Be-
dogni et al. (10), reconstructed these cases with titanium 
plates and local soft and hard-tissue flaps and achieved 
a complete remission in 80% of patients after 24 months 
of follow-up. HBO therapy also showed positive effects 
in 62,5% of the cases of another study (15) but it should 
not be considered as an individual treatment modality 
for BRONJ at this time (16,17).
In the retrospective study of Hoefert and Eufinger (4), 
cases were divided into two groups treated with the 
same surgical technique but with two different antibio-
tic regimens. After 17 months of follow-up, the cases 
treated with a long-term preoperative antibiotic therapy 
had better results (complete healing in 87% of the cases 
in contrast to 47% with a short-term regimen). Further-
more, the authors state that the combination of extensive 
surgical bone resection with antimicrobial mouth rinses 
and prolonged antibiotic therapy may lead to complete 
healing (4). Ferlito et al. (14) also emphasised the impor-
tance of the use of suitable antibiotics, anti-inflammato-
ries, analgesics and mouthrinses to minimise pain and 
infection before the formation of a bony sequestrum.
Graziani et al. (18) and Carlson and Basile (19) propose 
a more aggressive management, based in bone resec-
tions, to treat BRONJ patients. Regardless the stage of 
the disease, areas of necrotic bone that are a constant 
source of soft tissue irritation should be removed in or-
der to allow a proper healing (3,17).
Most patients under bisphosphonate therapy are usually 
also receiving other therapeutic agents, such as corticos-
teroids, statins, and other chemotherapeutic agents, all 
of which could have a significant effect on the incidence 
of BRONJ (7). This statement has been supported on the 
recent update position paper of the AAOMS published 
in October 2014 (17).
Tension-free closure of the wound and an adequate bone 
resection are key factors for the treatment prognosis. 
Although it is extremely difficult to quantify the amount 
of bone that should be removed, bleeding is considered a 
sign of healthy bone, although the reliability of this sign 
is a controversial subject (11,20,21). 
Laser might be an interesting alternative to conventional 
bone removal devices. Vescovi et al. (22) proposed the use 
of Erbium-doped Yttrium Aluminium Garnet (Er:YAG) 
laser, achieving a complete remission of the signs and 
symptoms in all the patients of their trial. The same au-
thors also established the use of low-level laser therapy 
(LLLT) in BRONJ treatment using a Neodymium-doped 
Yttrium Aluminium Garnet (Nd:YAG) laser.
A combined treatment protocol consisting in pharma-
cological therapy, surgical treatment with platelet rich 
plasma (PRP) and laser phototherapy (LPT) using In-
dium-Gallium-Alluminium-Phosphide (InGaAlP) diode 
laser, has shown positive results (64% success rate) in 
the management of BRONJ patients (12). Some authors 
(13,23) use PRP or plasma rich in growth factors (PRGF) 
due to its capacity to improve soft tissue healing.
The routine use of antibiotics (both preoperative and 
postoperative), and of antiseptic mouthrinses generally 
with chlorhexidine digluconate 0.2% is recommended 
by the vast majority of authors. Bacteria play an impor-
tant role in the physiopathology of BRONJ and seem to 
be directly involved in the development of necrotic le-
sions and in the inhibition of epithelial regeneration over 
the exposed bone (24). Once extended BRONJ lesions 
are present, systemic antibiotics are not able to reach the 
affected area due to the lack of vascularisation. In fact, 
Junquera et al. (9) and Mücke et al. (11) concluded that 
BRONJ patients with advanced stages would not impro-
ve when treated only with antibiotics since progression 
of the lesions will occur. 
However, a conservative approach based in the admi-
nistration of antibiotics, antiseptics, analgesics, antifun-
gals and fluorides, seems to be particular effective in 
the initial stages of the disease (stages 0 and I) (25,26). 
Both Nicolau-Galitis et al. (25) and Fortuna et al. (26) 
obtained, respectively, a 91,5% and a 84,6% success ra-
tes with this approach. Other authors (27,28) also used 
minimally invasive protocols with good results. Indeed, 
Montebugnoli et al. (28), concluded that there was no 
significant difference in the amount of necrotic bone bet-
ween the samples of cases treated with surgery and the 
ones treated only with antibiotics.
Considering the results of the publications included 
in our review, the success rates of BRONJ surgical 
treatment vary between 58-100%. The different surgical 
techniques, the sample characteristics (type of IVBP; 
duration of BP therapy; presence of additional risk fac-
tors and location of the lesions), the lack of well-defined 
success criteria and the additional treatments performed 
(antibiotics, antiseptics and LLLT) justify this variation 
of outcomes. Our results seem to support the results of 
a recent systematic review (29), which concluded that 
extensive surgery and laser seem to provide the best 
healing results. On the other hand, the level of scientific 
evidence provided by the studies published to date (type 
2 and 3), does not allow drawing any sound conclusions. 
Indeed, there is a great need to perform well design con-
trolled randomized clinical trials in order to increase the 
degree of recommendation. In addition, in order to faci-
litate future research on this topic, it would be especially 
interesting to unify the success criteria.
Conclusions
- The absence of level 1 scientific evidence studies does 
not allow recommending any treatment approach for 
BRONJ patients. There is clearly a need to performed 
large sample controlled randomized clinical trials with 
an adequate follow-up. 
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- A wide range of treatment protocols has been published 
with varying results. The lack of standardized success 
criteria makes comparisons between treatments very 
difficult. 
- In light presentations of BRONJ (classified as degree 
0 and 1), a conservative approach based in prescription 
of antibacterial agents seems to be the most adequate 
approach. On the other hand, a surgical treatment based 
in sequestrectomy, surgical debridement and/or bone re-
moval provides successful treatment outcomes, with a 
58-100% success rate.
- All treatments described have a low grade of recom-
mendation according to the SORT criteria.
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